Diageo (NYSE:DEO) vs. Arcadia Biosciences (NASDAQ:RKDA) Financial Contrast

Arcadia Biosciences (NASDAQ:RKDA) and Diageo (NYSE:DEO) are both consumer staples companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.

Insider and Institutional Ownership

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 9.0% of Diageo shares are owned by institutional investors. 8.2% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Arcadia Biosciences and Diageo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcadia Biosciences	1	0	0	0	1.00
Diageo	2	4	6	0	2.33

Diageo has a consensus price target of $106.25, suggesting a potential upside of 10.43%. Given Diageo’s stronger consensus rating and higher possible upside, analysts plainly believe Diageo is more favorable than Arcadia Biosciences.

Profitability

This table compares Arcadia Biosciences and Diageo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Arcadia Biosciences	-195.94%	-113.73%	-68.47%
Diageo	N/A	N/A	N/A

Valuation and Earnings

This table compares Arcadia Biosciences and Diageo”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcadia Biosciences	$4.86 million	0.35	-$2.34 million	($5.73)	-0.12
Diageo	$19.64 billion	2.73	$2.35 billion	N/A	N/A

Diageo has higher revenue and earnings than Arcadia Biosciences.

Risk and Volatility

Arcadia Biosciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Diageo has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Summary

Diageo beats Arcadia Biosciences on 9 of the 12 factors compared between the two stocks.

About Arcadia Biosciences

Arcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.

About Diageo

Diageo plc, together with its subsidiaries, engages in the production, marketing, and sale of alcoholic beverages. The company offers scotch, gin, vodka, rum, raki, liqueur, wine, tequila, Chinese white spirits, cachaça, and brandy, as well as beer, including cider and flavored malt beverages. It also provides Chinese, Canadian, Irish, American, and Indian-Made Foreign Liquor whiskies, as well as flavored malt beverages, ready to drink, and non-alcoholic products. The company provides its products under the Johnnie Walker, Crown Royal, J&B, Buchanan’s, Smirnoff, Cîroc, Ketel One, Captain Morgan, Baileys, Don Julio, Casamigos, Tanqueray, Guinness, Shui Jing Fang, Yenì, McDowell’s, Don Papa, Aviation American, Seagram, Seagram’s 7 Crown, Zacapa, Black Dog, Black & White, Signature, Royal Challenge, Godawan, Antiquity, Gordon’s, Old Parr, Windsor, Bundaberg, Ypióca, Bulleit, and Bell’s brand names. It operates in the United States, the United Kingdom, Türkiye, Australia, Korea, India, Greater China, Brazil, Mexico, South Africa, Nigeria, and internationally. The company was incorporated in 1886 and is headquartered in London, the United Kingdom.